ArticleBrain, behavior, & immunity - health2025
The predictivity of hematological parameters and related inflammatory biomarkers of male subjects with chronic polysubstance use disorder.
Article in Brain, behavior, & immunity - health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SIRI, SII, and PNI in psychiatric patients with positive urinary drug metabolites: association with immune and nutritional biomarkers.BMC psychiatry · 2026Article
- Hematological Inflammatory Indices and Coagulation Parameters in Individuals with Substance Use Disorder: A Comparative Study with Healthy Controls.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polysubstance use disorder (PSUD) is a chronic disease with adverse clinical outcomes. Hematological properties and related inflammatory biomarkers have not been investigated in PSUD. This study aimed to investigate the alterations in hematologic and related inflammatory parameters among subjects with PSUD. Methods: A total of sixty subjects were included, thirty chronic PSUD subjects and thirty control subjects. Venous blood was withdrawn from participants, and complete blood count was conducted. Related inflammatory biomarkers were calculated, including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), neutrophil-to-monocyte ratio (NMR), derived neutrophil-to-lymphocyte ratio (dNLR), and systemic inflammation index (SII). Results: Between study groups, we reported significant differences in red cell count, hematocrit, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration (P < 0.001). As compared to control subjects, PSUD subjects had significantly higher neutrophil counts that coincided with significantly lower monocyte counts (P < 0.001). These findings corresponded to significantly higher NLR (2.88 ± 0.21 vs. 1.92 ± 0.13), dNLR (2.39 ± 0.97 vs.1.43 ± 0.08), NMR (35.1 ± 4.8 vs.8.3 ± 0.5), LMR (13.3 ± 1.7 vs. 4.6 ± 0.3) and SII (683.0 ± 56.9 vs. 424.3 ± 30.2) among PSUD subjects (P < 0.001). Receiver operating characteristic analysis revealed areas under the curves for NMR, LMR, dNLR, NLR, and SII of 0.983, 0.829, 0.811, 0.766, and 0.779, respectively (P < 0.001). Conclusion: Chronic PSUD alters erythrocyte indices that define mild erythrocytic hyperchromasia and may suggest membrane damage. Furthermore, higher hematological inflammatory biomarkers imply the contribution of systemic inflammation in the pathophysiology of PSUD and suggest their diagnostic predictivity of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.